Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Proviva Therapeutics (Hong Kong) Limited has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners. The portfolio is also spread across 3 distinct art units, indicating a unique examiner and art unit for every pending case. This distribution across 3 distinct art units suggests that the company's innovations cover multiple specialized sub-fields within biotechnology.
GUSTILO, ESTELLA M is the busiest examiner, responsible for 1 busiest examiner pending office action. This represents one of the 3 pending office actions. Because the 3 pending actions are handled by 3 distinct examiners in 3 distinct art units, the company faces a diverse set of examination environments. Practitioners should monitor the different art units to ensure that the prosecution of the 3 pending office actions remains consistent despite the lack of centralized oversight.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (50%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAYLOR, LIA ELAN | 2 | 64.2% | +29.5% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
| BERHANE, SELAM | 1 | 59.1% | +56.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19466032 | IL-2 PROCYTOKINE ANTIBODY FUSION PROTEINS | TAYLOR, LIA ELAN | — |
| 18459142 | IL-15 PROCYTOKINE ANTIBODY FUSION PROTEINS | GUSTILO, ESTELLA M | — |
| 18361357 | IL-2 PROCYTOKINE ANTIBODY FUSION PROTEINS | TAYLOR, LIA ELAN | — |
| 17413786 | IL-15 COMPOSITIONS AND METHODS OF USE THEREOF | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1646 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19466032 | IL-2 PROCYTOKINE ANTIBODY FUSION PROTEINS | TAYLOR, LIA ELAN | 1641 | §103§112DP | Final Rejection | — | Pending | Jan 30, 2026 |
| 18459142 | IL-15 PROCYTOKINE ANTIBODY FUSION PROTEINS | GUSTILO, ESTELLA M | 1646 | §112 | Non-Final OA | — | Pending | Aug 31, 2023 |
| 18361357 | IL-2 PROCYTOKINE ANTIBODY FUSION PROTEINS | TAYLOR, LIA ELAN | 1641 | §103§112DP | Non-Final OA | — | Pending | Jul 28, 2023 |
| 17413786 | IL-15 COMPOSITIONS AND METHODS OF USE THEREOF | BERHANE, SELAM | 1675 | §112 | Final Rejection | — | Pending | Jun 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProviva Therapeutics (Hong Kong) Limited has 4 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Lia Elan Taylor has the most, with 2 of Proviva Therapeutics (Hong Kong) Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
